Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study
Related Posts
Pahulu I, Calumpit M, Tominez P, Shih JJ, Ebrahimi S, Deville NV, Samoa R, Moin T, Sedrak MS, Valle LF, Steinberg M, Kishan AU, Ganz[...]
Veliova M, Ferreira CM, Montales KP, Villalobos F, Brownstein AJ, Acín-Pérez R, Ferreira GS, Jones AE, Stiles L, Divakaruni AS, Liesa M, Shirihai OS, Oliveira[...]
Pak K, Leng M, Nguyen J, Moussa K, Gish R, Han SH, Pockros P. Regional Comparisons of the Prevalence and Socioeconomics of Hepatitis Delta Virus[...]